For instance, while 70–90% of relapsed and/or refractory ALL patients show durable responses to CD19-targeted CAR-T therapy, recent data indicate that 30–70% of these patients develop disease resistance due to CD19 antigen downregulation or loss [17,18]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.